CNBC October 23, 2021
Katie Brigham

It was Jan. 24, 2020 when BioNTech CEO Uğur Şahin knew that Covid-19 was likely to become a global pandemic. 

Though it was over a month and a half before the World Health Organization officially declared a pandemic, Sahin met with his wife, BioNTech’s co-founder and chief medical officer Özlem Türeci. Together, they agreed to redirect most of the company’s resources to developing a vaccine. 

“He approached me and explained his thoughts and his his fears,” Türeci said. “And it was immediately clear to both of us that the technology we had, and which we had already clinically developed, that could help to ensure a rapid response.”


Today's Sponsors


Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Healthcare System, Pharma / Biotech, Public Health / COVID
COVID-19 : Measuring viral RNA to predict which patients will die
Thanks to CRISPR, this at-home COVID-19 test is both fast and accurate
Covid has made biotech companies the hot new tech sector as investor demand drives record IPOs
Messenger RNA vaccine pioneer Katalin Karikó shares her long journey to Covid-19 vaccines
Could editing the genomes of bats prevent future coronavirus pandemics? Two scientists think it’s worth a try